Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × trastuzumab deruxtecan × Sarcoma × Clear all

Phase

Status

Recruiting 3 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Sarcoma 1

Conditions

Interventions

Specimen Handling 3 pembrolizumab 2 trastuzumab deruxtecan 1 tivozanib 1 pegamotecan 1 fludarabine phosphate 1 atezolizumab 1 X-Rays 1 Surgical Procedures, Operative 1 RFB4(dsFv)-PE38 recombinant immunotoxin 1 Magnetic Resonance Spectroscopy 1 Health Care Economics and Organizations 1 Cyclophosphamide 1 Biopsy 1 Biomarkers 1 Antibodies, Monoclonal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04616560 2026-03-18

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

National Cancer Institute (NCI)

Phase 2 Suspended

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡